NEWS
Our Latest News
ARCHIMED closes MED IV fund at €1.5 billion ($1.75 billion) hard cap, three times oversubscribed, in less than six months of fundraising.
ARCHIMED’s MED II sells DIESSE, returning 4.6x to shareholders
January
27,
2025
ARCHIMED earns 5x its investment, selling a majority of Ad-Tech to Tokyo-listed Nihon Kohden
November
26,
2024
ARCHIMED acquires SeqCenter, a fast-growing player in cutting-edge DNA and RNA gene sequencing
November
8,
2024
368